Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 4 (1)

Trial Status

Unknown1
Not Yet Recruiting1
Enrolling By Invitation1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06787430Phase 4Not Yet RecruitingPrimary

Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI

NCT07382700Enrolling By InvitationPrimary

Metabolic Characteristics of Plasma OxPLs in STEMI Patients.

NCT05308329Unknown

Kitasato PCI Registry

Showing all 3 trials

Research Network

Activity Timeline